vs
Side-by-side financial comparison of KEMPER Corp (KMPR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
KEMPER Corp is the larger business by last-quarter revenue ($1.1B vs $622.0M, roughly 1.8× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.7%, a 35.1% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -4.7%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -0.5%).
Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
KMPR vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $622.0M |
| Net Profit | $-8.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | -0.7% | 34.4% |
| Revenue YoY | -4.7% | 4.8% |
| Net Profit YoY | -108.2% | 2.9% |
| EPS (diluted) | $-0.03 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $1.2B | $609.3M | ||
| Q2 25 | $1.2B | $578.7M | ||
| Q1 25 | $1.2B | $568.2M | ||
| Q4 24 | $1.2B | $593.6M | ||
| Q3 24 | $1.2B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | $1.1B | $568.0M |
| Q4 25 | $-8.0M | $214.2M | ||
| Q3 25 | $-21.0M | $288.2M | ||
| Q2 25 | $72.6M | $30.2M | ||
| Q1 25 | $99.7M | $238.3M | ||
| Q4 24 | $97.4M | $208.2M | ||
| Q3 24 | $73.7M | $544.0M | ||
| Q2 24 | $75.4M | $102.0M | ||
| Q1 24 | $71.3M | $4.8M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 10.1% | 50.2% | ||
| Q1 24 | 7.6% | -13.0% |
| Q4 25 | -0.7% | 34.4% | ||
| Q3 25 | -1.7% | 47.3% | ||
| Q2 25 | 5.9% | 5.2% | ||
| Q1 25 | 8.4% | 41.9% | ||
| Q4 24 | 8.2% | 35.1% | ||
| Q3 24 | 6.3% | 96.3% | ||
| Q2 24 | 6.7% | 19.0% | ||
| Q1 24 | 6.2% | 0.8% |
| Q4 25 | $-0.03 | $0.49 | ||
| Q3 25 | $-0.34 | $0.67 | ||
| Q2 25 | $1.12 | $0.07 | ||
| Q1 25 | $1.54 | $0.55 | ||
| Q4 24 | $1.51 | $0.46 | ||
| Q3 24 | $1.14 | $1.21 | ||
| Q2 24 | $1.16 | $0.23 | ||
| Q1 24 | $1.10 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | $943.5M | $9.0B |
| Stockholders' EquityBook value | $2.7B | $9.7B |
| Total Assets | $12.5B | $19.6B |
| Debt / EquityLower = less leverage | 0.35× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | $371.2M | $938.9M | ||
| Q2 25 | $407.6M | $631.9M | ||
| Q1 25 | $545.3M | $1.1B | ||
| Q4 24 | $1.0B | $929.0M | ||
| Q3 24 | $696.9M | $950.1M | ||
| Q2 24 | $539.1M | $1.8B | ||
| Q1 24 | $520.7M | $843.0M |
| Q4 25 | $943.5M | $9.0B | ||
| Q3 25 | $943.1M | $8.9B | ||
| Q2 25 | $942.6M | $8.0B | ||
| Q1 25 | $942.1M | $7.6B | ||
| Q4 24 | $1.4B | $7.6B | ||
| Q3 24 | $1.4B | $7.6B | ||
| Q2 24 | $1.4B | $7.6B | ||
| Q1 24 | $1.4B | $6.1B |
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.7B | $9.6B | ||
| Q2 25 | $370.0M | $9.5B | ||
| Q1 25 | $366.0M | $9.8B | ||
| Q4 24 | $2.8B | $10.3B | ||
| Q3 24 | $2.8B | $10.3B | ||
| Q2 24 | $358.0M | $9.8B | ||
| Q1 24 | $2.6B | $9.9B |
| Q4 25 | $12.5B | $19.6B | ||
| Q3 25 | $12.4B | $19.3B | ||
| Q2 25 | $12.6B | $18.3B | ||
| Q1 25 | $12.5B | $17.6B | ||
| Q4 24 | $12.6B | $18.2B | ||
| Q3 24 | $12.6B | $18.0B | ||
| Q2 24 | $12.6B | $17.7B | ||
| Q1 24 | $12.6B | $16.1B |
| Q4 25 | 0.35× | 0.92× | ||
| Q3 25 | 0.35× | 0.93× | ||
| Q2 25 | 2.55× | 0.84× | ||
| Q1 25 | 2.57× | 0.78× | ||
| Q4 24 | 0.50× | 0.74× | ||
| Q3 24 | 0.50× | 0.74× | ||
| Q2 24 | 3.88× | 0.78× | ||
| Q1 24 | 0.54× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.0M | $827.1M |
| Free Cash FlowOCF − Capex | $166.2M | — |
| FCF MarginFCF / Revenue | 14.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $553.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.0M | $827.1M | ||
| Q3 25 | $139.9M | $702.6M | ||
| Q2 25 | $89.6M | $364.0M | ||
| Q1 25 | $180.0M | $596.1M | ||
| Q4 24 | $175.1M | $742.5M | ||
| Q3 24 | $141.9M | $703.6M | ||
| Q2 24 | $22.9M | $658.2M | ||
| Q1 24 | $43.0M | $664.6M |
| Q4 25 | $166.2M | — | ||
| Q3 25 | $133.4M | — | ||
| Q2 25 | $82.0M | — | ||
| Q1 25 | $172.3M | — | ||
| Q4 24 | $165.4M | — | ||
| Q3 24 | $131.4M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $27.7M | — |
| Q4 25 | 14.7% | — | ||
| Q3 25 | 10.8% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 1.23× | 12.06× | ||
| Q1 25 | 1.81× | 2.50× | ||
| Q4 24 | 1.80× | 3.57× | ||
| Q3 24 | 1.93× | 1.29× | ||
| Q2 24 | 0.30× | 6.45× | ||
| Q1 24 | 0.60× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
